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Abstract
Increased pain sensitivity after opioid administration (opioid-induced hyperalgesia) and/or repeated painful stimuli is an
individually varying and clinically important phenomenon. The functional polymorphism (val
158met) of the Catechol-O-
methyltransferase (COMT) gene regulates the metabolism of dopamine/noradrenaline. Individuals homozygous for the
met
158 allele have been reported to have increased pain sensitivity and there are findings of lower m-opioid system
activation during sustained pain. We hypothesized that met/met individuals would exhibit higher pain sensitization and
opioid-induced hyperalgesia in response to repeated pain stimuli and an intravenous injection of an opioid drug.
Participants were 43 healthy subjects who went through an experiment where five blocks of pain were induced to the hand
using a heat probe. After each stimulus subjects rated the pain on a visual analogue scale (VAS) from 0 mm (no pain) to
100 mm (worst possible pain). Before the second stimulus there was an intravenous injection of a rapid and potent opioid
drug.
At baseline there was no difference in pain ratings between the COMTval
158met genotypes, F(2, 39),1. However, a
repeated measures ANOVA for all five stimuli revealed a main effect for COMTval
158met genotype, F(2, 36)=4.17, p=0.024.
Met/met individuals reported significantly more pain compared to val/val, p=0.010. A pairwise comparison of baseline and
the opioid intervention demonstrated that analgesia was induced in all groups (p=0.042) without a separating effect for
genotype (n.s).
We suggest that the initial response of the descending pain system is not influenced by the COMTval
158met polymorphism
but when the system is challenged the difference is revealed. An important clinical implication of this may be that the
COMTval
158met related differences may be more expressed in individuals where the inhibitory system is already challenged
and sensitive, e.g. chronic pain patients. This has to be proven in future studies where the impact of the COMTval
158met
polymorphism on opioid treatment in patients is addressed.
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Introduction
The subjective sensitivity to pain, as indicated by self-report in
response to a pain stimulus, differs between individuals. Some are
more sensitive than others and the subjective experience of pain is
created from a complex interaction of afferent sensory input and
cognitive processing of this stimulus [1]. The pain experience is
modulated on all levels of the neural axis. Several brain networks
act as potent modulators of pain and studies have shown that
prefrontal brain regions are involved in the inhibition of
nociception [2]. A suggested common pathway for these
mechanisms is the recruitment of the descending pain defense
system which is partly modulated by the central catecholaminergic
systems [3], i.e. noradrenaline and dopamine. The function of
these systems is genetically influenced by the activity of the
catecholamine breakdown enzyme Catechol-O-methyltransferase
(COMT) [4]. A single-nucleotide polymorphism (SNP) in the
coding region of its gene (COMTval
158met, rs4680) controls the
enzyme activity and there are three possible genotypes of this
polymorphism: met/met, met/val and val/val, representing the
substitution of the amino acid valine for methionine at codon 158.
The breakdown of dopamine and noradrenaline is up to 4 times
higher for the valine allele compared to methionine, resulting in
different levels of synaptic dopamine/noradrenalin following
neurotransmitter release [4]. This polymorphism has previously
been associated with aspects of memory function [5], anxiety [6]
and regulation of pain sensitivity (7Individuals homozygous for the
COMTmet
158 allele have been reported to have increased pain
sensitivity during sustained/repeated pain stimulation [7–8] but
not following single pain stimuli [7,9] compared to individuals
homozygous for the COMTval
158allele. This indicates that
COMT influences central pain modulation. The latter is
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sustained pain stimulation in met/met individuals compared to
val/val [8]. Furthermore, an increased m-opioid receptor binding
potential was found in certain brain regions in met/met
individuals compared to val/val, which was interpreted as a
compensatory mechanism [8]. This means that the COMT-
val
158met polymorphism could affect the response to opioid drugs
which was previously observed in a clinical setting including a
group of cancer patients [10–13]. However, the relationship
between the COMTval
158met polymorphism and opioid analge-
sia was never investigated experimentally in humans. This is the
first controlled experiment where the design aimed at clarifying
the mechanisms behind a specific genetic influence on opioid
analgesia in humans.
The endogenous opioid system is highly involved in endogenous
regulation of pain [2] and therefore influences important aspects of
what constitutes a pain response. The strong association between
the COMTval
158met polymorphism and prefrontal- and opioid
function makes it a suitable candidate when investigating
mechanisms underlying the placebo effect. Placebo analgesia
involves biological mechanisms that recruit endogenous pain relief
through strong influence on the subject’s psychological expectancy
and appraisal. When designing this study, we had much interest in
addressing the genetic underpinnings for placebo analgesia.
However, our experiment revealed that the genetic trait of the
COMTval
158met polymorphism had a profound effect on the
conditioning step of the planned placebo intervention. This means
that the opioid exposure introduced differences insensitivity to the
following pain stimuli and thus confounding the original design.
Here, we report on this effect as it represents an important step in
understanding the mechanisms of pain sensitization and opioid-
induced hyperalgesia.
We describe the association between the COMTval
158met
polymorphism and the analgesic effect of a short acting opioid on
sensitivity to repeated pain stimuli in healthy subjects. Specifically,
we investigate how the COMTval
158met polymorphism influences
the interindividual differences in response to intravenous injection
of Remifentanil and placebo on repeated heat pain stimulation.
Based on previous findings of increased m-opioid receptor binding
potential in met/met individuals, we would expect an increased
analgesic effect of short acting opioids in met/met individuals
compared to val/val. However, the reduced capacity to activate
the m-opioid system due to reduced concentrations of endogenous
opioids [8] would predict increased pain sensitivity during
repeated pain stimulation due to less effective recruitment of
endogenous pain inhibition leading to a more pronounced
sensitization in met/met individuals.
Methods
Participants were 43 healthy subjects (12 men and 31 women,
mean age 26 years), recruited via advertising. To meet the
inclusion criteria subjects had to be over 18 years old, right-
handed, take no medications (female subjects were allowed to take
contraceptive pills), have no history of drug abuse, chronic pain or
psychiatric disorders. Subjects were recruited from a variety of
institutions in order to represent all sorts of educational and
professional backgrounds. All subjects were Caucasian. The
distribution of the different alleles of the COMTval
158met
polymorphism in the present sample and the sex distribution in
the different genetic groups are seen in Table 1. The genotype
distribution for COMTval
158met in this sample did not differ
significantly from the one predicted by the Hardy-Weinberg
equilibrium, x2=0.183, p=0.67.
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of Karolinska Institutet (Reference
number 2005/950–31/1). All patients provided written informed
consent for the collection of samples and subsequent analysis.
The subjects went through an experiment where pain was
repeatedly induced to different locations of the dorsum of the hand
using a 363 cm heat probe (Medoc TSA, Medoc, Israel). Hence,
no part of the skin was affected by the heat probe more than once
as to prevent increased sensitivity to the pain stimulus by means of
local mechanisms. The order of the different positions on the hand
was counter-balanced and in total five blocks (T1–T5) of 30
seconds of tonic heat (48u Celsius) was administered. After each
stimulus T (T1–T5) subjects were asked to rate the pain on a visual
analogue scale (VAS) ranging from 0 mm (no pain) to 100 mm
(worst possible pain). There was at least a 10 minutes pause
between all pain stimuli. Only one block (T2) included an active
drug treatment. Immediately before T2 there was an intravenous
injection of a rapid and potent anesthetic drug Remifentanil (4-
(Methoxycarbonyl)-4-[(1-oxopropyl) phenylamino]-1 - piperidine
propa-noic acid methyl ester) which is an opioid drug acting on m-
type receptors. It has a rapid onset of action and a very short
duration. Patients were informed that the drug used in the
experiment had a very short time of action and that the effect
would last only for the duration of the pain stimulation. The time
for a 50% reduction in the effect site concentration is about
3.65 min and the terminal elimination half-life 10.2 min at a dose
of 2 g/kg. The dose used in our experiment (0.08 mg/kg body
weight) was dramatically smaller than in the given example but we
still employed a 1 hour pause before the next stimulus (T3) in
order to minimize a possible residual drug effect. The optimal dose
of Remifentanil was determined in a pilot study where the desired
analgesic effect was validated. At T4 there was an intravenous
injection of a placebo substance (saline) together with the
instruction that also this injection included an anesthetic. All
other pain stimuli in the experiment had no concomitant
treatment or oral suggestions. During the experiment both the
subject and experimentor were blinded as to the genetic category
of the subject. The experiment lasted for approximately two hours.
Samples of 20 ml whole blood were taken venously and stored
at 280uC until DNA extraction, which was performed robotized
by the local Biobank (KI Biobank, Karolinska Institutet, Stock-
holm) using standard methods (Autopure LS system, Gentra
Systems, Minneapolis, MN). DNA yield was measured with UV at
260 nm and with the 260/280 ratio as a quality check. For
genotyping of COMTval
158met (rs4680) a commercial TaqManH
assay was used. Fluorescence measurements were performed using
the ABI HT7900 (Applied Biosystems, Foster City, CA) and the
SDS 2.2.1 software (Applied Biosystems). All genotypes were
determined twice.
Table 1. Distribution of the different COMTval
158met
polymorphisms for male and female subjects in the present
study (n=43).
Subjects COMT
met/met met/val val/val
Male 5 5 2
Female 5 15 11
Total 10 20 13
doi:10.1371/journal.pone.0006016.t001
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COMTval
158met genotypes for the first exposure to heat pain by
means of a univariate ANOVA (dependent variable VAS ratings,
fixed factor COMTval
158met genotype).
The VAS ratings were normalized to the initial baseline rating,
i.e. each participant’s T2, T3, T4 and T5 rating was individually
divided by the participant’s baseline rating. This is a way to
control the effect of individual differences in response style, i.e.
answering in the high end or low end of the VAS scale when
reporting the subjective level of pain.
For the main analysis a repeated measures ANOVA was
performed where the normalized pain responses for T1–T5 were
used as within-subject factor and the three different COMT-
val158met genotypes were used as between-subject factors.
Thereafter, we probed for an overall effect of time (T), as well as
a COMTval
158met related difference in the analgesic response to
Remifentanil by means of pairwise comparisons derived from the
above model.
To explore the main effects and a possible interaction for the
three provocations in the post Remifentanil period a repeated
measures ANOVA was perfomed for T3–T5 (between subjects
factor was COMTval
158met genotype, within subjects factor was
the three different timepoints).
In order to control for any possible differences in pain ratings
betweenmen and women,sex was added ascovariateinthe analysis.
In all performed analyses Greenhouse Geisser corrections were
applied when appropriate. The statistical software SPSS 16.0 was
used. Hardy-Weinberg equilibrium was calculated by Pearson’s
goodness-of-fit x2 (df=1) using a website (http://ihg2.helmholtz-
muenchen.de/cgi-bin/hw/hwa1.pl).
Results
At baseline (T1) there was no difference in pain ratings between
the COMTval
158met genotype groups, F(2, 40),1, p=0.741.
When looking at the pain reports over all five timepoints (T1–
T5) for COMTval
158met (T6COMT), a repeated measurements
ANOVA revealed a main effect for COMTval
158met genotype,
F(2, 36)=4.17, p=0.024 (see Figure 1). Individuals homozygous
for the met allele reported significantly more pain as compared to
individuals homozygous for the val allele, p=0.010 and also
heterozygous, p=0.042. Carriers of one or two val alleles did not
differ in their pain reports, p=0.265. The main effect for T was
significant, F(3,109)=5.70, p=0.001. There was a significant
interaction for T6COMT, F(6, 109)=3.38, p=0.004. For the
total experiment there was no main effect of sex, F(1,36),1,
p=0.128, or interaction of T6sex, F(3,109),1, p=0.329.
A pairwise comparison for T1–T2 demonstrated that analgesia
was induced by Remifentanil (T2) in all groups without separating
the different genotype groups (p=0.042). This means that there
was no significant effect of genotype on the direct analgesic
response to the opioid.
In the post Remifentanil period (T3–T5) there was a significant
difference between the COMTval
158met genotype groups,
F(2,36)=6.48, p=0.004, with highest VAS ratings given by the
met/met group and lowest in the val/val with the heterozygous in
between. Individuals homozygous for the met allele reported
significantly more pain than individuals homozygous for the val
allele, p=0.002, and heterozygous, p=0.014, both of which did
not differ from each other. There was also a main effect for T with
decreasing VAS reported with T, F(2,64)=5.39, p=0.009.
However there was no interaction T6COMT F(4,64),1,
p=0.708. Thus, there was no effect of the placebo manipulation
at T4 related to genotype group. There was no main effect of sex
for the post Remifentanil period, F(1,36)=2.67, p=0.11, or
interaction of T6sex, F(2,64)=0.73, p=0.47.
Discussion
Our data demonstrate that the COMT val
158met genotype has
a marked influence on the pain experience following standard heat
pain provocations in the period following an opiate injection. Also,
several other findings should be pointed out: We found that the
reaction to the initial pain stimulus was the same for individuals
with different COMTval
158met genotypes. This is in concert with
the report of Kim et al (2004) as well as Diatchenko et al (2006)
that used a repeated pain provocation design. In that report, there
were no differences based on COMTval
158met genotypes for the
initial pain provocations, but a temporal heat pain summation was
noted that differed between genotypes, with the most expressed
summation expressed in the met/met group. In that study a fast
repeat of the stimuli was used and also the same anatomical site for
stimulation was employed in all cases. In our study we used
different anatomical locations and had minimally 10 min between
stimuli and a one hour washout of Remifentanil between T2 and
T3. We therefore do not see the data as directly comparable
except for the initial time point. The lack of influence of
COMTval
158met genotypes in the analgesic response to the
intravenous opioid administration is important. It suggests that the
initial response of the pain system is not influenced by the
COMTval
158met polymorphism but when the pain defense system
is challenged repeatedly, this specific genotype based difference
become apparent. Such a vulnerability effect has previously been
described for the COMTval
158met polymorphism in the effect on
working memory in relation to aging [14]. A possible clinical
implication of this may be that the COMTval
158met related
differences may be more expressed in individuals where the
inhibitory system is already challenged and the individual is
sensitive already from start, e.g. chronic pain patients.
When we analyzed all five stimulations in the experiment, there
was a difference in pain response for individuals with the different
Figure 1. Representation of the subjects’ pain ratings over the
five different time points (T). Pain was rated using the visual
analogue scale (VAS) ranging from ‘‘no pain’’ (0 mm VAS) up to ‘‘worst
possible pain’’ (100 mm VAS). Identical pain stimulation was given at all
five timepoints. Prior to T2 there was an intravenous injection of
Remifentanil and prior to T4 there was an intravenous injection of saline
(placebo). All pain ratings represented in this figure are individually
normalized to baseline (T1).
doi:10.1371/journal.pone.0006016.g001
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158met genotypes. The repeated measures ANOVA
revealed main effects for T as well as COMT genotype and also a
significant interaction. Further analyses revealed that the main
effect for COMTval
158met genotype was driven by the three post
Remifentanil provocations (T3–T5), which demonstrated a
consistent effect for COMTval
158met with no interaction with
T. The met/met group exhibited the highest pain ratings, the val/
val group the lowest and the heterozygous group had an
intermediate response. Due to the notable effect of the
COMTval
158met polymorphism on pain sensitivity over time, it
was not possible to detect an effect of the placebo manipulation at
T4. The factor ‘‘sex’’ was always added as covariate in order to
control for the possibility that it could be a confounding factor,
explaining differences in pain sensitivity. Our conclusion from the
statistical analysis is that the influence of COMTval
158met on pain
sensitivity is not affected by sex. However, the distribution between
the different genotypes was not the same for males and females in
this study, limiting the possibility to fully interpret the impact of
COMTval
158met between men and women.
The increased pain sensitivity for the met/met individuals
following Remifentanil could be caused by reduced efficacy of
endogenous pain modulation and/or by increased susceptibility to
opioid-induced hyperalgesia. Opioid-induced hyperalgesia has
been reported following a single intravenous infusion of Remi-
fentanil in humans [5]. The mechanisms involved in opioid-
induced hyperalgesia overlap to a large degree with those
implicated in pain sensitization following repeated or tonic
noxious stimuli such as activation of N-methyl-D-aspartate
(NMDA) receptors and activation of descending pain facilitatory
mechanisms [15–18]. The design of our study does not permit a
definite distinction between pain sensitization due to opioid
exposure or repeated painful stimulation. In both cases the result
is increased pain sensitivity, but the mechanisms leading to this are
different. However, the fact that the post Remifentanil pain ratings
decreased over time favor opioid induced hyperalgesia as a likely
explanation. If our results would be due to a sensitization through
repeated pain stimuli there would probably be a continuous
increase up to T5. Our results therefore suggest that the
COMTval
158met polymorphism could be important for the
understanding of why certain individuals are more prone to
develop opioid-induced hyperalgesia and tolerance to the
antinociceptive actions of opioids.
Regardless of the possible impact of COMTval
158met on pain
sensitization and/or opioid-induced hyperalgesia, results from the
present study support the hypothesis that the COMTval1
58met
polymorphism may influence the capacity for top-down regulation
of pain. The COMTval
158met polymorphism is a key regulator of
dopaminergic neurotransmission and has consistently been
associated with human prefrontal function. Studies show that the
effect of different COMTval
158met genotypes is stronger the more
it involves frontal cortical structures tuned by dopamine [5]. The
prefrontal cortex of the human brain is a key modulator for
descending inhibition of pain, which is partially mediated by
endogenous opioids and catecholaminergic mechanisms. These
mechanisms are triggered by repeated or tonic noxious stimuli,
which mean that the inhibitory effect kicks in only after a proper
activation of the pain suppressing system.
In a study by Zubieta et al. (2003) there was a significantly
reduced m-opioid response in the brain during pain in met/met
individuals in response to a tonic pain model where hypertonic
saline was continuously infused in the masseter muscle. There was
also an observation of differences between groups in the quantities
of hypertonic saline needed to maintain a stable pain level over
time, indicating that the met/met group needed less hypertonic
saline. The results from our present study validate the findings by
Zubieta et al (2003) by demonstrating increased pain sensitivity in
met/met individuals over time also following administration of
exogenous opioids.
The opioid injection given at T2 led to significant reduction in
pain, but there was no difference in effect between the three
different genotype groups. This negative result was different from
our hypothesis. We expected that there would be an increased
analgesic effect in met carriers compared to val/val since there are
reports of increased m-opioid receptor binding potentials and
possibly a decreased ability to recruit endogenous opioids. Hence,
the negative result for differences in opioid response suggests that
there is no difference in an initial opioid effect. However, with
repeated painful stimuli following this single opioid administration
the mechanisms that are associated with the COMT val
158met
polymorphism can be manifested. In the study by Zubieta et al
(2003) the correlation between pain sensitivity and genotype was
seen first after a prolonged pain stressor. Results from the present
study validate this also in response to exogenous opioids. Previous
results on the influence of the COMTval
158met polymorphism in
opioid treatment in a group of cancer patients [10–13] showed
that met/met individuals needed lower doses of morphine in order
to relieve pain. That can partly be explained by increased m-opioid
receptor binding potentials and possibly a decreased ability to
recruit endogenous opioids in met/met individuals [8].
Originally there was also an intention to analyze the difference in
placebo response between the different COMTval
158met genotypes.
Instead the notable difference in pain sensitivity that developed over
time for the different COMTval
158met genotypes was discussed per
se. This leaves the placebo questions for future studies with
experimental designs that are not confounded by the difference in
pain sensitivity after an opioid injection and repeated pain stimuli.
The choice of genetic polymorphism was based on the empirical
evidence for the involvement of COMTval
158met in regulation of
pain, which allowed us to create a strong a priori hypothesis.
Compared to other possible choices, this is a functional polymor-
phism which means it has a well documented impact on
physiological processes, and in particular the enzyme activity of
COMT. Also, the frequency of the different alleles in this particular
polymorphism is fairly equal in distribution which makes it a good
candidate when one does not have access to a large group of
genotyped subjects. The relatively small number of subjects included
in this experiment is a limitation to the study. However, this is the
first experimental study on the COMTval
158met influence on opioid
anesthesia and the results could potentially be of high scientific and
clinical benefit. Including a small group of subjects means a greater
risk for false positives and the results should be carefully interpreted.
Therefore we hope for validation of these results in future studies
with more resources and subjects.
Here we demonstrate that the response dynamics following
opioid administration and repeated pain stimulation can be
stratified based on genotype. This emphasizes the complexity of
the mechanisms involved in pain inhibition.
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